이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Bionime 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

TWSE:4737 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (TWD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	1,858	-40	-308	101	N/A
3/31/2024	1,809	7	-305	95	N/A
12/31/2023	1,756	6	-238	203	N/A
9/30/2023	1,863	22	-163	297	N/A
6/30/2023	2,002	43	-109	284	N/A
3/31/2023	2,150	72	26	393	N/A
12/31/2022	2,211	91	-171	142	N/A
9/30/2022	2,091	95	-189	91	N/A
6/30/2022	2,023	115	-139	129	N/A
3/31/2022	1,862	89	-208	84	N/A
12/31/2021	1,850	87	-15	270	N/A
9/30/2021	1,879	101	2	254	N/A
6/30/2021	1,832	111	-58	205	N/A
3/31/2021	1,779	83	-62	204	N/A
12/31/2020	1,669	62	-79	218	N/A
9/30/2020	1,913	73	-20	270	N/A
6/30/2020	1,951	38	-4	247	N/A
3/31/2020	2,162	91	248	456	N/A
12/31/2019	2,173	106	267	406	N/A
9/30/2019	2,043	112	117	243	N/A
6/30/2019	2,113	132	55	208	N/A
3/31/2019	1,986	121	-98	64	N/A
12/31/2018	2,007	128	-47	122	N/A
9/30/2018	1,962	114	2	164	N/A
6/30/2018	1,842	135	40	166	N/A
3/31/2018	1,821	137	N/A	99	N/A
12/31/2017	1,820	150	N/A	30	N/A
9/30/2017	1,771	174	N/A	134	N/A
6/30/2017	1,780	181	N/A	275	N/A
3/31/2017	1,791	192	N/A	420	N/A
12/31/2016	1,740	179	N/A	458	N/A
9/30/2016	1,654	143	N/A	441	N/A
6/30/2016	1,637	119	N/A	373	N/A
3/31/2016	1,571	91	N/A	228	N/A
12/31/2015	1,610	99	N/A	200	N/A
9/30/2015	1,634	101	N/A	271	N/A
6/30/2015	1,591	82	N/A	305	N/A
3/31/2015	1,571	72	N/A	354	N/A
12/31/2014	1,525	54	N/A	360	N/A
9/30/2014	1,446	22	N/A	272	N/A
6/30/2014	1,459	43	N/A	148	N/A
3/31/2014	1,536	72	N/A	165	N/A
12/31/2013	1,561	90	N/A	129	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 4737 의 예상 수익 증가율이 절약률( 1% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 4737 의 수익이 TW 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 4737 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 4737 의 수익이 TW 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 4737 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 4737 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Bionime 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased to NT$85.00

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q2, 2024 Results on Aug 08, 2024

Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Upcoming dividend of NT$2.00 per share

Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to NT$2.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: NT$0.10 (vs NT$1.50 in FY 2022)

Bionime Corporation, Annual General Meeting, Jun 28, 2024

New minor risk - Earnings quality

Bionime Corporation Announces TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License

Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer

Second quarter 2023 earnings released: EPS: NT$0.17 (vs NT$0.65 in 2Q 2022)

Bionime Corporation Announces Appointment of Aling Lai as New Member to the Remuneration Committee

Upcoming dividend of NT$2.10 per share at 2.7% yield

Bionime Corporation Appoints Aling Lai as Additional Member of Audit Committee

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to NT$85.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System

Second quarter 2022 earnings released: EPS: NT$0.65 (vs NT$0.22 in 2Q 2021)

Less than half of directors are independent

Upcoming dividend of NT$2.00 per share

Bionime Corporation Announces Members of the First Order Audit Committee of the Company

Less than half of directors are independent

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bionime Corporation Announces Replacement of the Representative of the Its Institutional Director

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.68 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.26 loss in 2Q 2020)

Upcoming dividend of NT$2.06 per share

First quarter 2021 earnings released: EPS NT$0.20 (vs NT$0.14 loss in 1Q 2020)

These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Full year 2020 earnings released: EPS NT$1.06 (vs NT$1.85 in FY 2019)

Bionime Corporation Announces Dividend for the Year 2020

Bionime Corporation, Annual General Meeting, Jun 24, 2021

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Investor sentiment improved over the past week

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

New 90-day low: NT$62.30

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Bionime Corporation Announces Change to the Principal Accounting Officer of the Company

New 90-day low: NT$64.50

How Has Bionime (TPE:4737) Allocated Its Capital?

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

New 90-day low: NT$68.20

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Third quarter 2020 earnings released: EPS NT$0.68

First half earnings released

Upcoming Dividend of NT$1.99 Per Share

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견